

=> file medline embase biosis biotechds uspatfull		
COST IN U.S. DOLLARS	SINCE FILE	TOTAL
	ENTRY	SESSION
FULL ESTIMATED COST	0.42	0.42

FILE 'MEDLINE' ENTERED AT 17:45:54 ON 03 JAN 2006

FILE 'EMBASE' ENTERED AT 17:45:54 ON 03 JAN 2006
Copyright (c) 2006 Elsevier B.V. All rights reserved.

FILE 'BIOSIS' ENTERED AT 17:45:54 ON 03 JAN 2006
Copyright (c) 2006 The Thomson Corporation

FILE 'BIOTECHDS' ENTERED AT 17:45:54 ON 03 JAN 2006
COPYRIGHT (C) 2006 THE THOMSON CORPORATION

FILE 'USPATFULL' ENTERED AT 17:45:54 ON 03 JAN 2006
CA INDEXING COPYRIGHT (C) 2006 AMERICAN CHEMICAL SOCIETY (ACS)

=> s human protein kinase and dna
L1 521 HUMAN PROTEIN KINASE AND DNA

=> dup rem l1
PROCESSING COMPLETED FOR L1
L2 436 DUP REM L1 (85 DUPLICATES REMOVED)

=> s l2 and HPK3P23
L3 2 L2 AND HPK3P23

=> d l3 1-2 ibib ab

L3 ANSWER 1 OF 2 BIOTECHDS COPYRIGHT 2006 THE THOMSON CORP. on STN
ACCESSION NUMBER: 2004-13996 BIOTECHDS

TITLE: New **human protein kinase**,
designated **HPK3P23**, and encoding polynucleotides
for diagnosing, preventing or treating kinase-related
diseases, such as cancer, Parkinson's disease, inflammation,
stroke or cardiovascular disorders;
vector-mediated protein-kinase gene transfer and
expression in host cell for recombinant protein
production, drug screening and gene therapy

AUTHOR: LIU W; WU L
PATENT ASSIGNEE: WYETH; LIU W; WU L
PATENT INFO: WO 2004032877 22 Apr 2004
APPLICATION INFO: WO 2003-US32302 10 Oct 2003
PRIORITY INFO: US 2002-417209 10 Oct 2002; US 2002-417209 10 Oct 2002
DOCUMENT TYPE: Patent
LANGUAGE: English
OTHER SOURCE: WPI: 2004-340806 [31]

AB DERWENT ABSTRACT:

NOVELTY - An isolated polynucleotide comprising (I), is new.

DETAILED DESCRIPTION - An isolated polynucleotide comprising (I), is new. (I) comprises: (a) a nucleic acid sequence encoding a sequence of 1016 amino acids (S2) fully defined in the specification; (b) a variant of (a), where the variant and the nucleic acid sequence have at least 91% sequence identity; or (c) a sequence that hybridizes under stringent conditions to a polynucleotide consisting of a sequence of 3644 bp (S1) fully defined in the specification, or its complement, where the polynucleotide consists of at least 1000 or at least 2600 nucleic acids and does not include any of the 4 sequences of 1601-2562 bp (S5-8) given in the specification, or its complement, and where the polynucleotide encodes a protein kinase. INDEPENDENT CLAIMS are also included for: (1) an isolated polypeptide comprising a fragment, or a variant of the fragment, of S2, where the fragment comprises at least 500 consecutive amino acid residues of S2; (2) an antibody capable of binding to S2 with

a binding affinity of no less than 105 M-1; (3) an **HPK3P23** detection kit comprising the above antibody or a probe that hybridizes to the nucleotide sequence of S1 or its complement; (4) a host cell containing the above polynucleotide or its variant; (5) a transgenic non-human animal comprising the above polynucleotide or its variant; (6) identifying an agent capable of binding to **HPK3P23** kinase, comprising contacting a candidate agent with a polypeptide comprising S2, or its fragment or variant; and detecting the binding between the candidate agent and the polypeptide; (7) identifying an agent capable of modulating the level of activity of **HPK3P23** kinase, comprising contacting a candidate agent with a polypeptide comprising S2 or its fragment or variant; and detecting a change in the level of an activity of the polypeptide; (8) a pharmaceutical composition for preventing or treating **HPK3P23**-related diseases, comprising a pharmaceutical carrier and an agent that modulates an **HPK3P23** activity or the **HPK3P23** gene expression; (9) preventing or treating an **HPK3P23**-related disease in a subject, comprising introducing into the subject an amount of the pharmaceutical composition cited above; and (10) inhibiting the expression of the gene in the cell by RNA interference comprising introducing the above polynucleotide into a cell which expresses human **HPK3P23** gene, thus, .

BIOTECHNOLOGY - Preferred Polynucleotide: The nucleic acid sequence is selected from S1 or a sequence having 220860 bp (S3) fully defined in the specification, its complement, and a nucleic acid sequence that differs from S1 or S3 or its complement due to the degeneracy of the genetic code. The variant and the nucleic acid sequence have at least 95% sequence identity. The polynucleotide is capable of inhibiting human **HPK3P23** gene expression by RNA interference. It comprises a siRNA sense strand or a siRNA antisense strand selected from those listed in the specification. Preferred Polypeptide: The polypeptide fragment consists of S2. The variant and the fragment have at least 95% sequence identity. Preferred Transgenic Animal: At least one allele of a gene in the genome of the animal is functionally disrupted, where the gene encodes a polypeptide that has at least 70% sequence identity to S2. Preparation: The polynucleotide was prepared using standard isolation techniques.

ACTIVITY - Cytostatic; Antiasthmatic; Antiparkinsonian; Antiinflammatory; Antipsoriatic; Antirheumatic; Antiarthritic; Osteopathic; Immunosuppressive; Cardiovascular-Gen.; Ophthalmological; Cerebroprotective; Anticonvulsant; Vasotropic. No biological data given.

MECHANISM OF ACTION - Gene Therapy.

USE - The composition and methods are useful for diagnosing, prognosing, preventing and treating kinase-related diseases, in particular, diseases associated with aberrant expression of **HPK3P23**, such as cancer, asthma, Parkinson's disease, inflammation, psoriasis, rheumatoid arthritis, osteoporosis, graft-versus-host disease, cardiovascular disorders, autoimmune disorders, retinal detachment, stroke, epilepsy or ischemia/reperfusion.

ADMINISTRATION - Administration can be parenteral (e.g. intravenous, intradermal or subcutaneous), oral (e.g. inhalational), transdermal (topical), transmucosal, or rectal. No dosage given.

EXAMPLE - No suitable example given. (210 pages)

L3 ANSWER 2 OF 2 USPATFULL on STN

ACCESSION NUMBER: 2004:126910 USPATFULL

TITLE: Compositions, organisms and methodologies employing a novel human kinase

INVENTOR(S): Liu, Wei, Sudbury, MA, UNITED STATES
Wu, Leeyang, Lexington, MA, UNITED STATES

PATENT ASSIGNEE(S): Wyeth, Madison, NJ (U.S. corporation)

	NUMBER	KIND	DATE
PATENT INFORMATION:	US 2004096889	A1	20040520
APPLICATION INFO.:	US 2003-684190	A1	20031010 (10)

	NUMBER	DATE
PRIORITY INFORMATION:	US 2002-417209P	20021010 (60)
DOCUMENT TYPE:	Utility	
FILE SEGMENT:	APPLICATION	
LEGAL REPRESENTATIVE:	NIXON PEABODY, LLP, 401 9TH STREET, NW, SUITE 900, WASHINGTON, DC, 20004-2128	
NUMBER OF CLAIMS:	23	
EXEMPLARY CLAIM:	1	
NUMBER OF DRAWINGS:	3 Drawing Page(s)	
LINE COUNT:	7960	

CAS INDEXING IS AVAILABLE FOR THIS PATENT.

AB This invention provides compositions, organisms and methodologies employing a novel **human protein kinase, HPK3P23**. The novel human kinase has sequence homology to the catalytic domains of several protein kinases. The gene encoding this novel protein kinase is localized in or near the 3p23 locus of the human chromosome 3. The sequence similarity between the novel human protein and the catalytic domain of protein kinases indicates that the novel human protein may function as a protein kinase.

=> d his

(FILE 'HOME' ENTERED AT 17:45:02 ON 03 JAN 2006)

FILE 'MEDLINE, EMBASE, BIOSIS, BIOTECHDS, USPATFULL' ENTERED AT 17:45:54
ON 03 JAN 2006

L1 521 S HUMAN PROTEIN KINASE AND DNA
L2 436 DUP REM L1 (85 DUPLICATES REMOVED)
L3 2 S L2 AND HPK3P23

=> log y

COST IN U.S. DOLLARS	SINCE FILE ENTRY	TOTAL SESSION
FULL ESTIMATED COST	11.29	11.71

STN INTERNATIONAL LOGOFF AT 17:48:14 ON 03 JAN 2006